Deepti Pandey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Deepti Pandey has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Akila Elias
Department of Pharmacognosy Al‐Ameen College of Pharmacy Bangalore India
1 shared publication - Aleesha Mujeeb Shaheen
Department of Pharmaceutical Chemistry Al‐Ameen College of Pharmacy Bengaluru India
1 shared publication - Bipindra Pandey
Department of Pharmacy, Madan Bhandari Academy of Health Sciences, Hetauda 44107, Nepal
1 shared publication - Mahalakshmi Suresha Biradar
Department of Pharmaceutical Chemistry Al‐Ameen College of Pharmacy Bengaluru India
1 shared publication - Monica Arora
Faculty of Health Sciences, Villa College, Male’, Republic of Maldives
1 shared publication - Nagaraja Sreeharsha
Department of Pharmaceutical Sciences College of Clinical Pharmacy, King Faisal University Al‐Ahsa Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 11 November 2025
- Published by Wiley in Food Science & Nutrition
- Vol. 13 (11)
Phytochemical Profile and α‐Amylase Inhibitory Activity of Pomegranate Peel Extract: An In Silico and In Vitro Investigation
Diabetes is among the top ten causes of mortality and morbidity. Diabetes has been increasing faster in low‐ and middle‐income nations than it has been rising in high‐income countries. This study explores the phytochemical profiling and in vitro α‐amylase inhibitory activity of the methanolic extract of Nepalese‐origin pomegranate peels. Phytochemical analysis using FT‐IR and LC–MS identified key bioactive compounds, including ellagic acid, punicalagin, punicalin, gallic acid, and ellagic acid‐O‐xylopyranoside, contributing to the observed enzymatic inhibition. Molecular docking studies revealed strong binding affinities of punicalagin (−11.6 kcal/mol) and ellagic acid‐O‐xylopyranoside (−10.6 kcal/mol) to α‐amylase, suggesting potential antidiabetic properties. MD simulations confirmed the stability of these interactions over a 100 ns timeframe, reinforcing their role in enzyme inhibition. The in vitro α‐amylase inhibition assay demonstrated comparable activity of pomegranate peel extract (IC 50 = 137.74 μg/mL) to reference drug acarbose (IC 50 = 222.19 μg/mL). These findings provide molecular insights into the bioactivity of pomegranate peel extracts, highlighting their potential in diabetes management.
- 11 November 2025
- Published by Wiley in Food Science & Nutrition
- Vol. 13 (11)
Open AccessPhytochemical Profile and α‐Amylase Inhibitory Activity of Pomegranate Peel Extract: An In Silico and In Vitro Investigation
Diabetes is among the top ten causes of mortality and morbidity. Diabetes has been increasing faster in low‐ and middle‐income nations than it has been rising in high‐income countries. This study explores the phytochemical profiling and in vitro α‐amylase inhibitory activity of the methanolic extract of Nepalese‐origin pomegranate peels. Phytochemical analysis using FT‐IR and LC–MS identified key bioactive compounds, including ellagic acid, punicalagin, punicalin, gallic acid, and ellagic acid‐O‐xylopyranoside, contributing to the observed enzymatic inhibition. Molecular docking studies revealed strong binding affinities of punicalagin (−11.6 kcal/mol) and ellagic acid‐O‐xylopyranoside (−10.6 kcal/mol) to α‐amylase, suggesting potential antidiabetic properties. MD simulations confirmed the stability of these interactions over a 100 ns timeframe, reinforcing their role in enzyme inhibition. The in vitro α‐amylase inhibition assay demonstrated comparable activity of pomegranate peel extract (IC 50 = 137.74 μg/mL) to reference drug acarbose (IC 50 = 222.19 μg/mL). These findings provide molecular insights into the bioactivity of pomegranate peel extracts, highlighting their potential in diabetes management.